Bayer G4A Welcomes Carenostics to 2022 Digital Health Partnerships

Bayer G4A today announces Carenostics as a new partner to join the G4A portfolio as part of the Digital Health Partnerships. Carenostics will receive a 200.000€ convertible loan, coaching from industry experts, and executive mentorship from Bayer. Carenostics is a healthcare AI startup dedicated to addressing the underdiagnosis, undertreatment, and health disparities of chronic diseases by finding opportunities for earlier clinical intervention through machine learning on patients EHR data.

Carenostics was selected by Bayer G4A from hundreds of applications based on their strategic fit, product and technology, and the fact that their solution solves a pressing healthcare issue. Sophie Park, Managing Director for Investments and Partnerships at Bayer G4A Integrated Care: “We are excited to have Carenostics in our digital health portfolio for 2022. Their AI solution addresses health inequities across chronic diseases by offering providers, payers, and care management companies earlier intervention opportunities to tackle gaps in care across the care continuum. Their approach saves time, costs, increases the accuracy of diagnosis, and makes the communication between institutions, patients, and their HCP’s more efficient.”


Through Bayer G4A’s Digital Health Partnerships, the selected partner companies receive funding to accelerate market uptake as well as mentorship from Bayer experts and coaching from external industry experts in various fields such as market entry, GDPR & HIPAA, and financial planning. At G4A we tailor each partnership to the business needs and individual stages of our partner companies.


Bharat Rao, Co-Founder and CEO & Kanishka Rao, Co-Founder and COO: "We founded Carenostics with the goal of addressing the underdiagnosis, undertreatment, and health equity disparities of chronic conditions through AI and ML on latent patient data. Our vision is to transform healthcare into a data-driven paradigm where patient data is leveraged to make personalized patient recommendations for diagnostic and therapy decisions - to improve patient outcomes and reduce healthcare costs. We are thrilled to be partnering with Bayer to address the gaps in chronic disease care. Bayer's unparalleled depth of clinical expertise and industry knowledge will be essential to scaling our impact across the globe.”


You can still meet the Carenostics team in-person at HLTH at the G4A Pavilion (booth 557) until Wednesday, November 16.


The Bayer G4A Digital Health Partnerships changed to an open cycle model this year to capture high potential digital health companies throughout the whole year. Bayer G4A is currently looking for partners developing holistic digital health solutions in the areas of cardiovascular and cardiometabolic diseases, chronic kidney disease, and women’s health. Learn more here.